TLDR
- ARK sold 670,746 Personalised shares worth $10.7 million through its ARKG ETF on October 16.
- ARK bought 254,668 Freenome shares worth about $3.1 million.
- ARK also sold CareDx shares and bought Scribe Therapeutics shares.
- ARK bought 168,633 Rocket Lab shares worth about $9.3 million on Thursday.
- Rocket Lab pushed its Neutron rocket debut to 2027.
Cathie Wood’s ARK Invest made several trades this week, selling some healthcare stocks and buying others. It also added to its Rocket Lab position after the share price dropped.
ARK published its daily trades for Friday, October 16, 2026. The largest trade of the day was a sale of 670,746 shares of Personalised, Inc. through its ARKG ETF. The sale was worth $10,684,983.
This continues a trend from earlier in the week. ARK sold large amounts of Personalised stock on several days. The fund has been reducing its position in the company.
ARK Adds to Freenome and Scribe Therapeutics
On the buying side, ARK acquired 254,668 shares of Freenome, Inc. through ARKG. The purchase was worth $3,129,869. It adds to the fund’s recent buying of Freenome shares.
ARK also bought 29,416 shares of Scribe Therapeutics Inc. The total value was $609,499. The fund made smaller purchases of the stock earlier in the week.
ARK sold 59,477 shares of CareDx, Inc. through ARKG. The sale totaled $3,965,926. The fund has sold CareDx shares steadily over the past week.
Shares of the companies moved lower after the trades were reported. Freenome fell 4.40% and Scribe Therapeutics fell 3.09%. CareDx dropped 4.00% and Personalised slipped 1.76%. ARKG was down 5.16%.
ARK Buys Rocket Lab After Sell-Off
ARK also made a separate purchase in the space sector. On Thursday, ARK funds bought 168,633 shares of Rocket Lab valued at about $9.3 million.
The purchase came as Rocket Lab shares fell nearly 7%. The stock is down about 21% for the year. It fell another 7.98% in the latest session.
Investors are focused on Neutron, the company’s planned medium-lift rocket. Rocket Lab has pushed the first launch to 2027. Production issues required more work on the vehicle.
The delay pushes back a possible new source of revenue. Building the rocket also adds to spending. Rocket Lab reported negative free cash flow of $110 million in the second quarter.
The company’s current business offers some support. Its backlog reached $2.36 billion at the end of June. That is up 137% from a year earlier.
Rocket Lab also has an agreement covering 20 Electron launches. This adds to its future launch demand. Neutron’s schedule and development costs remain key factors for investors.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
